Metastatic renal cell carcinoma imaging evaluation in the era of anti-angiogenic therapies.
During the last decade, the arsenal of anti-angiogenic (AAG) agents used to treat metastatic renal cell carcinoma (RCC) has grown and revolutionized the treatment of metastatic RCC, leading to improved overall survival compared to conventional chemotherapy and traditional immunotherapy agents. AAG a...
| Published in: | Abdominal Radiology Vol. 41; no. 6; pp. 1086 - 1100 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Journal Article |
| Published: |
Springer Nature
Jun2016
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=115863279&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 115863279 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 2366004X JT14 jtl: Abdominal Radiology issn: 2366004X maglogo: N pubinfo: dt: Jun2016 vid: 41 iid: 6 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 115863279 10.1007/s00261-016-0742-7 115863279 ppf: 1086 ppct: 14 formats: fmt: @attributes: type: P tig: atl: Metastatic renal cell carcinoma imaging evaluation in the era of anti-angiogenic therapies. aug: au: Sirous, Reza Henegan, John Zhang, Xu Howard, Candace Souza, Frederico Smith, Andrew affil: Department of Radiology, University of Mississippi Medical Center, 2500 North State Street Jackson 39216 USA sug: ab: During the last decade, the arsenal of anti-angiogenic (AAG) agents used to treat metastatic renal cell carcinoma (RCC) has grown and revolutionized the treatment of metastatic RCC, leading to improved overall survival compared to conventional chemotherapy and traditional immunotherapy agents. AAG agents include inhibitors of vascular endothelial growth factor receptor signaling pathways and mammalian target of rapamycin inhibitors. Both of these classes of targeted agents are considered cytostatic rather than cytotoxic, inducing tumor stabilization rather than marked tumor shrinkage. As a result, decreases in tumor size alone are often minimal and/or occur late in the course of successful AAG therapy, while tumor devascularization is a distinct feature of AAG therapy. In successful AAG therapy, tumor devascularization manifests on computed tomography images as a composite of a decrease in tumor size, a decrease in tumor attenuation, and the development of tumor necrosis. In this article, we review Response Evaluation Criteria in Solid Tumors (RECIST)-the current standard of care for tumor treatment response assessment which is based merely on changes in tumor length-and its assessment of metastatic RCC tumor response in the era of AAG therapies. We then review the features of an ideal tumor imaging biomarker for predicting metastatic RCC response to a particular AAG agent and serving as a longitudinal tumor response assessment tool. Finally, a discussion of the more recently proposed imaging response criteria and new imaging trends in metastatic RCC response assessment will be reviewed. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|